| Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C group study. | |
| | |
MedLine Citation:
|
PMID: 22481452 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: Hepatitis C virus genotype 4 is predominant in the Middle East and Northern Africa, even if it has recently spread to Southern Europe. Data about the treatment of post-liver transplantation (LT) genotype 4 hepatitis C recurrence are scarce. We report a retrospective analysis of post-LT genotype 4 hepatitis C treatment in 9 Italian transplant centres, focusing on the overall survival rates and treatment outcome. RESULTS: Among 452 recipients, we identified 17 HCV genotype 4 patients (16 males, 1 female) transplanted between 1998 and 2007. All patients received combined antiviral treatment with conventional doses of interferon (recombinant or pegylated) and ribavirin after histological diagnosis of hepatitis C recurrence. The observed overall survival after LT was 100% at 1 year and 83.3% at 5 years. More than 1/3 (35.3%) of patients achieved a sustained virological response (SVR) and 40% (data available in 15 subjects) an early virological response (EVR), which was significantly associated with the achievement of SVR (overall accuracy: 85.7%; predictive values of EVR absence/presence 80/88.8%; chi-square p < 0.05). CONCLUSION: In conclusion, in post-LT genotype 4 hepatitis C treatment, SVR rates are similar to genotype 1. Patients who don't show an EVR are not likely to achieve a SVR. |
| | |
Authors:
|
Francesca Romana Ponziani; Alessandro Milani; Antonio Gasbarrini; Raffaella Zaccaria; Raffaella Viganò; Maria Francesca Donato; Maria Cristina Morelli; Lucia Miglioresi; Luisa Pasulo; Maria Rendina; Daniele Di Paolo; Maria Marino; Pierluigi Toniutto; Stefano Fagiuoli; Maurizio Pompili |
Publication Detail:
|
Type: Journal Article; Multicenter Study |
Journal Detail:
|
Title: Annals of hepatology Volume: 11 ISSN: 1665-2681 ISO Abbreviation: Ann Hepatol Publication Date: 2012 May-Jun |
Date Detail:
|
Created Date: 2012-04-06 Completed Date: 2012-08-23 Revised Date: 2013-05-16 |
Medline Journal Info:
|
Nlm Unique ID: 101155885 Medline TA: Ann Hepatol Country: Mexico |
Other Details:
|
Languages: eng Pagination: 338-42 Citation Subset: IM |
Affiliation:
|
AISF RECOLT-C group: Catholic University of Rome, Italy. francesca.ponziani@yahoo.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antiviral Agents / therapeutic use* Cohort Studies Drug Therapy, Combination Female Genotype* Hepacivirus / genetics* Hepatitis B, Chronic / epidemiology*, therapy* Humans Interferon-alpha / therapeutic use Italy Liver Transplantation* Male Middle Aged Polyethylene Glycols / therapeutic use Recombinant Proteins / therapeutic use Recurrence Retrospective Studies Ribavirin / therapeutic use Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 0/Interferon-alpha; 0/Polyethylene Glycols; 0/Recombinant Proteins; 0/peginterferon alfa-2a; 36791-04-5/Ribavirin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hepatitis B virus prevalence and vaccination response in health care workers and students at the Fed...
Next Document: Serum adipocyte fatty acid binding protein in liver transplant recipients and the metabolic syndrome...